Green Campaign Gears Up Against Biotech Patenting

17 December 1997

With the adoption of the "common position" on the biotechnologypatenting directive by European Union ministers only just past (ie November 27), there is mounting evidence that environmental groups across Europe are starting afresh to mount opposition to the directive, in preparation for its return to the European Parliament for second reading.

The revitalized Green campaign has already involved the Green group of the European Parliament hosting a conference of anti-biotechnology activists including clinical geneticists, animal welfare groups and patient groups, devoted to defeating the "life patenting" directive.

Meanwhile, as far away as Bangkok, Thailand, delegations from eight developing countries, again prompted by Green activists, have met to discuss rules of consent for the patenting of genetic materials originating from indigenous peoples - a key issue which will beits fought over in the European Parliament.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight